论文部分内容阅读
目的探讨临床贝那普利对糖尿病肾病尿微量白蛋白的影响,探讨其作用机制。方法选取郑州大学第五附属医院自2007年4月至2010年3月收治的100例糖尿病肾病患者随机分为观察组(贝那普利治疗组)和对照组(常规降糖组)各50例,治疗4周后比较两组患者的尿微量白蛋白排泄率(UAE)。结果①两组患者治疗前UAE、GFR水平差异不大(P>0.05),治疗4周后观察组较对照组差异有统计学意义(P<0.05)。②观察组患者出现轻微头痛2例,嗜睡1例,经调整用药后消失,未见其他不良反应。结论贝那普利可显著改善糖尿病肾病肾功能,降低尿微量白蛋白排泄率,且用药安全性较高,值得推广应用。
Objective To investigate the clinical effect of benazepril on diabetic microalbuminuria in diabetic nephropathy and to explore its mechanism. Methods One hundred patients with diabetic nephropathy who were admitted to the Fifth Affiliated Hospital of Zhengzhou University from April 2007 to March 2010 were randomly divided into observation group (benazepril treatment group) and control group (conventional hypoglycemic group), 50 cases each After 4 weeks of treatment, urinary albumin excretion rate (UAE) was compared between the two groups. Results ① There was no significant difference in UAE and GFR levels between the two groups before treatment (P> 0.05). After 4 weeks of treatment, the difference between the observation group and the control group was statistically significant (P <0.05). ② In the observation group, 2 cases of mild headache and 1 case of drowsiness disappeared after adjustment, and no other adverse reactions were observed. Conclusion Behenopril can significantly improve the renal function of diabetic nephropathy, reduce the urinary albumin excretion rate, and the drug is safe and should be widely applied.